MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

TG Therapeutics Inc

Avatud

SektorTervishoid

39.75 1.02

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

39.33

Max

41.01

Põhinäitajad

By Trading Economics

Sissetulek

19M

23M

Müük

24M

108M

P/E

Sektori keskmine

246.467

57.333

Aktsiakasum

0.15

Kasumimarginaal

21.566

Töötajad

338

EBITDA

17M

33M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+6.7% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

30. apr 2025

Turustatistika

By TradingEconomics

Turukapital

912M

5.8B

Eelmine avamishind

38.73

Eelmine sulgemishind

39.75

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

TG Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. aug 2024, 20:01 UTC

Tulu

IBD 50 Stock TG Therapeutics Breaks Out Bullishly After 'Solid' Quarter -- IBD

Võrdlus sarnastega

Hinnamuutus

TG Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

6.7% tõus

12 kuu keskmine prognoos

Keskmine 43 USD  6.7%

Kõrge 55 USD

Madal 11 USD

Põhineb 6 Wall Streeti analüütiku instrumendi TG Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

5

Osta

0

Hoia

1

Müü

Tehniline skoor

By Trading Central

38.41 / 40.35Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bullish Evidence

Keskpikk perspektiiv

Neutral Evidence

Pikk perspektiiv

Bullish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.